![Professor David Hunter](https://thelimbic.com/wordpress/wp-content/uploads/2015/06/David-Hunter...003-300x242.jpg)
Professor David Hunter
Intra-articular injection of a liposomal formulation of dexamethasone sodium phosphate (DSP) is showing efficacy in reducing knee OA pain, Australian research suggests.
Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, told ACR Convergence 2023 that TLC599 uses multi-layer lipid membranes to encapsulate the dexamethasone which allows for a controlled release.
“It also provides free DSP for some immediate effect and a depot compartment of DSP for sustained release,” he said.
Professor Hunter said a phase 2 study published last year [link here] found a single dose of TLC599 12 mg improved pain on a visual analogue scale (VAS) and pain, stiffness and function on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) scales through to 24 weeks.
Now, a phase 3 RCT conducted in the US and Australia has compared TLC599 with placebo and DSP 4mg in 500 patients with Kellgren-Lawrence grade 2-3 OA of the knee, average daily pain (ADP) scores of 5-9 on a scale of 0-10 in the index knee, and a WOMAC pain score of ≥6 on a scale of 0-20.
Patients had a mean age of 61 years, BMI of 31, and had been diagnosed with OA for about eight years.
The study found ADP, WOMAC pain and WOMAC function at 12 weeks all favoured TLC599 compared to placebo with a significantly greater proportion of TLC599 patients having a 50% improvement in pain compared to placebo (48% v 36%; p<0.05).
For the most part, the findings extended out to 24 weeks. For example with WOMAC pain, TLC599 remained numerically superior to placebo at all time points through to week 24.